What is the incidence of lung cancer? Experts say this about the incidence of lung cancer

What is the incidence of lung cancer?

In recent years, the incidence of lung cancer in my country has been on the rise. In particular, the frequent smog weather across the country has further aroused the whole society's high attention to the high incidence of lung cancer. Recently, Roche Diagnostics announced that the new ElecsysproGRp test has been officially approved for marketing in China at the beginning of this year. It has good differential diagnostic value for small cell lung cancer and benign lung diseases, which helps clinicians to formulate reasonable treatment plans. It is understood that early small cell lung cancer is difficult to detect through chest CT examination. Therefore, experts recommend that people at high risk of lung cancer should add serum tumor marker tests to their physical examinations.

80% of lung cancer patients are diagnosed in the late stage

According to the statistics of the 2012 Tumor Registration Annual Report, lung cancer has replaced liver cancer as the leading cause of death from malignant tumors in my country. Currently, one in every four deaths from malignant tumors in my country is caused by lung cancer. Industrial waste gas, automobile exhaust emissions, air pollution, tobacco smoke, kitchen fumes and house decoration material pollution, personality factors (psychological pollution), etc. are all important factors leading to the high incidence of lung cancer.

Lung cancer is mainly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). SCLC cancer cells grow faster and are more malignant than NSCLC. Distant metastasis usually occurs in the early stages, and it is difficult to detect early suspected patients through imaging methods. Currently, the treatment of SCLC is mainly chemotherapy combined with radiotherapy.

proGRp can effectively identify small cell lung cancer

Given that the histological classification of lung cancer has a decisive influence on the treatment method and prognosis of patients, it is necessary to make differential diagnosis of lung cancer patients as early as possible. Only with a clear diagnosis can the appropriate treatment plan be selected. It is understood that as a powerful supplement to histopathology and imaging examinations, the new tumor marker proGRp (progastrin-releasing peptide) is tested in serum and plasma samples, which can provide important reference value for the management of lung cancer patients.

According to experts, the combined detection of serological tumor markers can improve the clinical value of sensitivity and specificity in lung cancer diagnosis. When the National Health and Family Planning Commission organizes experts from multiple disciplines to revise the 2014 edition of the "Guidelines for the Diagnosis and Treatment of Primary Lung Cancer", it will briefly explain the clinical scientific application of lung cancer tumor markers.